A Phase 1 interventional study of Vortioxetine in Severe Hepatic Impairment, sponsored by Takeda. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-01-05.
Sponsored by Takeda · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the pharmacokinetics of vortioxetine and its metabolites Lu AA34443 and Lu AA39835 following a single oral dose administration of vortioxetine 5 mg in participants with severe hepatic impairment compared to healthy participants.
The drug being tested in this study is called vortioxetine. Vortioxetine is being tested to assess how it moves throughout the body in people with severe hepatic impairment compared to people with normal hepatic function. This study looked at lab results in people who took vortioxetine.
The study enrolled 12 participants. Participants were assigned to one of the two treatment groups based on their hepatic function (severe hepatic impairment vs. normal hepatic function). All participants in both groups will receive one vortioxetine 5-mg tablet.
This single-center trial was conducted in the United States. The overall time to participate in this study was up to 58 days. Participants made 2 visits to the clinic, including one 12-day period of confinement to the clinic, and were contacted by telephone 30 days after last dose of study drug for a follow-up assessment.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
General:
Has a negative result at screening on the fecal occult blood screen.
Healthy Participants (Normal Hepatic Function):
The participant, in opinion of the investigator, is in good health as determined by a prestudy physical examination, medical history, vital signs, ECG, and the results of blood biochemistry, hematology, and serology tests, and urinalysis.
Participants with severe hepatic impairment:
Exclusion Criteria:
General:
Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse (defined as regular or daily consumption of more than 2 alcoholic units per day) within 1 year prior to the Screening Visit (1 unit=250 mL of beer or 20 mL of spirits or 1 glass [118 mL] of wine). Participants with severe hepatic dysfunction who test positive on the urine drug screen due to prescription drug use will be allowed to participate if approved by the principal investigator and the sponsor's medical monitor.
Healthy Participants (Normal Hepatic Function):
Has a positive test for fecal occult blood.
Participants with severe hepatic impairment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vortioxetine 5 mg, tablets, orally, once, on Day 1, in participants with normal hepatic function.
Drug: Vortioxetine
Vortioxetine 5 mg, tablets, orally, once, on Day 1, in participants with severe hepatic impairment.
Drug: Vortioxetine
Vortioxetine tablets
Also known as: Lu AA21004, BRINTELLIX
AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine
(AUC(0-tlqc) is a measure of total plasma exposure to the drug from time 0 to time of the last quantifiable concentration (AUC\[0-tlqc\]).
Time frame: Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose
AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine Metabolite Lu AA34443
(AUC(0-tlqc) is a measure of total plasma exposure to the drug from time 0 to time of the last quantifiable concentration (AUC\[0-tlqc\]).
Time frame: Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose
AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine Metabolite Lu AA39835
(AUC(0-tlqc) is a measure of total plasma exposure to the drug from time 0 to time of the last quantifiable concentration (AUC\[0-tlqc\]).
Time frame: Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose
AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Vortioxetine
AUC(0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.
Time frame: Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose
AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Vortioxetine Metabolite Lu AA34443
AUC(0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.
Time frame: Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose
Cmax: Maximum Observed Plasma Concentration for Vortioxetine
Maximum Observed Plasma Concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
Time frame: Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose
Cmax: Maximum Observed Plasma Concentration for Vortioxetine Metabolite Lu AA34443
Maximum Observed Plasma Concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
Time frame: Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose
Cmax: Maximum Observed Plasma Concentration for Vortioxetine Metabolite Lu AA39835
Maximum Observed Plasma Concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
Time frame: Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose
AUC(0-tlqc)u: Area Under the Unbound Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine
AUC(0-tlqc)u is a measure of total unbound plasma exposure to the drug from time 0 to time of the last quantifiable concentration (AUC\[0-tlqc\]u).
Time frame: Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose
AUC(0-inf)u: Area Under the Unbound Plasma Concentration-time Curve From Time 0 to Infinity for Vortioxetine
AUC(0-inf)u is a measure of total unbound plasma exposure to the drug from time zero extrapolated to infinity.
Time frame: Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose
Cmaxu: Maximum Observed Unbound Plasma Concentration for Vortioxetine
Maximum Observed Unbound Plasma Concentration (Cmaxu) is the peak unbound plasma concentration of a drug after administration, obtained directly from the unbound plasma concentration-time curve.
Time frame: Predose and 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, and 240 hours postdose
Participants took part in the study at 1 investigative site in the United States from 09 July 2014 (first participant signed the informed consent form) to 01 December 2014.
| Milestone | Vortioxetine 5 mg: Normal Hepatic Function Cohort | Vortioxetine 5 mg: Severe Hepatic Impairment Cohort |
|---|---|---|
| Started | 6 | 6 |
| Completed | 6 | 6 |
| Not completed | 0 | 0 |
(AUC(0-tlqc) is a measure of total plasma exposure to the drug from time 0 to time of the last quantifiable concentration (AUC\[0-tlqc\]).
| ng*hr/mL | Vortioxetine 5 mg: Normal Hepatic Function Cohort | Vortioxetine 5 mg: Severe Hepatic Impairment Cohort |
|---|---|---|
| AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine | 166.955 ± 45.1656 | 188.663 ± 68.5380 |
(AUC(0-tlqc) is a measure of total plasma exposure to the drug from time 0 to time of the last quantifiable concentration (AUC\[0-tlqc\]).
| ng*hr/mL | Vortioxetine 5 mg: Normal Hepatic Function Cohort | Vortioxetine 5 mg: Severe Hepatic Impairment Cohort |
|---|---|---|
| AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine Metabolite Lu AA34443 | 88.614 ± 53.1478 | 71.942 ± 48.9356 |
(AUC(0-tlqc) is a measure of total plasma exposure to the drug from time 0 to time of the last quantifiable concentration (AUC\[0-tlqc\]).
| ng*hr/mL | Vortioxetine 5 mg: Normal Hepatic Function Cohort | Vortioxetine 5 mg: Severe Hepatic Impairment Cohort |
|---|---|---|
| AUC(0-tlqc): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine Metabolite Lu AA39835 | 1.143 ± 1.2640 | 0.078 ± 0.1903 |
AUC(0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.
| ng*hr/mL | Vortioxetine 5 mg: Normal Hepatic Function Cohort | Vortioxetine 5 mg: Severe Hepatic Impairment Cohort |
|---|---|---|
| AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Vortioxetine | 187.202 ± 52.8692 | 288.053 ± 148.7612 |
AUC(0-inf) is a measure of total plasma exposure to the drug from time zero extrapolated to infinity.
| ng*hr/mL | Vortioxetine 5 mg: Normal Hepatic Function Cohort | Vortioxetine 5 mg: Severe Hepatic Impairment Cohort |
|---|---|---|
| AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Vortioxetine Metabolite Lu AA34443 | 122.899 ± 39.2417 | 124.708 ± 46.8665 |
Maximum Observed Plasma Concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
| ng/mL | Vortioxetine 5 mg: Normal Hepatic Function Cohort | Vortioxetine 5 mg: Severe Hepatic Impairment Cohort |
|---|---|---|
| Cmax: Maximum Observed Plasma Concentration for Vortioxetine | 2.078 ± 0.4675 | 1.670 ± 0.6135 |
Maximum Observed Plasma Concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
| ng/mL | Vortioxetine 5 mg: Normal Hepatic Function Cohort | Vortioxetine 5 mg: Severe Hepatic Impairment Cohort |
|---|---|---|
| Cmax: Maximum Observed Plasma Concentration for Vortioxetine Metabolite Lu AA34443 | 2.654 ± 1.6018 | 1.374 ± 0.7849 |
Maximum Observed Plasma Concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.
| ng/mL | Vortioxetine 5 mg: Normal Hepatic Function Cohort | Vortioxetine 5 mg: Severe Hepatic Impairment Cohort |
|---|---|---|
| Cmax: Maximum Observed Plasma Concentration for Vortioxetine Metabolite Lu AA39835 | 0.029 ± 0.0324 | 0.008 ± 0.0190 |
AUC(0-tlqc)u is a measure of total unbound plasma exposure to the drug from time 0 to time of the last quantifiable concentration (AUC\[0-tlqc\]u).
| ng*hr/mL | Vortioxetine 5 mg: Normal Hepatic Function Cohort | Vortioxetine 5 mg: Severe Hepatic Impairment Cohort |
|---|---|---|
| AUC(0-tlqc)u: Area Under the Unbound Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Vortioxetine | 1.611 ± 0.4937 | 1.653 ± 0.6882 |
AUC(0-inf)u is a measure of total unbound plasma exposure to the drug from time zero extrapolated to infinity.
| ng*hr/mL | Vortioxetine 5 mg: Normal Hepatic Function Cohort | Vortioxetine 5 mg: Severe Hepatic Impairment Cohort |
|---|---|---|
| AUC(0-inf)u: Area Under the Unbound Plasma Concentration-time Curve From Time 0 to Infinity for Vortioxetine | 1.806 ± 0.5685 | 2.558 ± 1.5242 |
Maximum Observed Unbound Plasma Concentration (Cmaxu) is the peak unbound plasma concentration of a drug after administration, obtained directly from the unbound plasma concentration-time curve.
| ng/mL | Vortioxetine 5 mg: Normal Hepatic Function Cohort | Vortioxetine 5 mg: Severe Hepatic Impairment Cohort |
|---|---|---|
| Cmaxu: Maximum Observed Unbound Plasma Concentration for Vortioxetine | 0.020 ± 0.0056 | 0.014 ± 0.0053 |
Collected over The first dose of study drug to within 32 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vortioxetine 5 mg: Normal Hepatic Function Cohort | — | 0/6 (0%) | 0/6 (0%) |
| Vortioxetine 5 mg: Severe Hepatic Impairment Cohort | — | 0/6 (0%) | 2/6 (33.3%) |
| Event | Vortioxetine 5 mg: Normal Hepatic Function Cohort | Vortioxetine 5 mg: Severe Hepatic Impairment Cohort |
|---|---|---|
| VomitingGastrointestinal disorders | 0/6 | 1/6 |
| Blood potassium increasedInvestigations | 0/6 | 1/6 |
| Age, Continuous(years) | Vortioxetine 5 mg: Normal Hepatic Function Cohort | Vortioxetine 5 mg: Severe Hepatic Impairment Cohort | Total |
|---|---|---|---|
| Mean | 50.3 ± 2.58 | 54.8 ± 6.79 | 52.6 ± 5.43 |
| Sex: Female, Male(Participants) | Vortioxetine 5 mg: Normal Hepatic Function Cohort | Vortioxetine 5 mg: Severe Hepatic Impairment Cohort | Total |
|---|---|---|---|
| Female | 1 | 1 | 2 |
| Male | 5 | 5 | 10 |
| Race/Ethnicity, Customized(participants) | Vortioxetine 5 mg: Normal Hepatic Function Cohort | Vortioxetine 5 mg: Severe Hepatic Impairment Cohort | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 6 | 12 |
| Not Hispanic or Latino | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Vortioxetine 5 mg: Normal Hepatic Function Cohort | Vortioxetine 5 mg: Severe Hepatic Impairment Cohort | Total |
|---|---|---|---|
| White | 6 | 6 | 12 |
| Region of Enrollment(participants) | Vortioxetine 5 mg: Normal Hepatic Function Cohort | Vortioxetine 5 mg: Severe Hepatic Impairment Cohort | Total |
|---|---|---|---|
| United States | 6 | 6 | 12 |
| Height(cm) | Vortioxetine 5 mg: Normal Hepatic Function Cohort | Vortioxetine 5 mg: Severe Hepatic Impairment Cohort | Total |
|---|---|---|---|
| Mean | 169.3 ± 10.31 | 165.7 ± 10.41 | 167.5 ± 10.06 |
| Weight(kg) | Vortioxetine 5 mg: Normal Hepatic Function Cohort | Vortioxetine 5 mg: Severe Hepatic Impairment Cohort | Total |
|---|---|---|---|
| Mean | 80.65 ± 13.261 | 82.17 ± 29.038 | 81.41 ± 21.537 |
| Body Mass Index (BMI)(kg/m^2) | Vortioxetine 5 mg: Normal Hepatic Function Cohort | Vortioxetine 5 mg: Severe Hepatic Impairment Cohort | Total |
|---|---|---|---|
| Mean | 28.02 ± 2.927 | 29.43 ± 7.554 | 28.73 ± 5.512 |
3 further baseline measures are reported on the registry.
The record gives a start of Jul 2014, a primary completion of Nov 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vortioxetine